Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial.

Fizazi K, Retz M, Petrylak DP, Goh JC, Perez-Gracia J, Lacombe L, Zschäbitz S, Burotto M, Mahammedi H, Gravis G, Bastos DA, McCune SL, Vázquez Limón JC, Kwan EM, Castellano D, Fléchon A, Saad F, Grimm MO, Shaffer DR, Armstrong AJ, Bhagavatheeswaran P, Amin NP, Ünsal-Kaçmaz K, Wang X, Li J, Loehr A, Pachynski RK

Open source

DOI: 10.1136/jitc-2022-004761
Published: 2022 Aug
Container: Journal for immunotherapy of cancer
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1136/jitc-2022-004761,
  title = {Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial.},
  author = {Fizazi K and Retz M and Petrylak DP and Goh JC and Perez-Gracia J and Lacombe L and Zschäbitz S and Burotto M and Mahammedi H and Gravis G and Bastos DA and McCune SL and Vázquez Limón JC and Kwan EM and Castellano D and Fléchon A and Saad F and Grimm MO and Shaffer DR and Armstrong AJ and Bhagavatheeswaran P and Amin NP and Ünsal-Kaçmaz K and Wang X and Li J and Loehr A and Pachynski RK},
  year = {2022},
  journal = {Journal for immunotherapy of cancer},
  doi = {10.1136/jitc-2022-004761},
  url = {https://doi.org/10.1136/jitc-2022-004761}
}

RIS

TY  - JOUR
TI  - Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial.
AU  - Fizazi K
AU  - Retz M
AU  - Petrylak DP
AU  - Goh JC
AU  - Perez-Gracia J
AU  - Lacombe L
AU  - Zschäbitz S
AU  - Burotto M
AU  - Mahammedi H
AU  - Gravis G
AU  - Bastos DA
AU  - McCune SL
AU  - Vázquez Limón JC
AU  - Kwan EM
AU  - Castellano D
AU  - Fléchon A
AU  - Saad F
AU  - Grimm MO
AU  - Shaffer DR
AU  - Armstrong AJ
AU  - Bhagavatheeswaran P
AU  - Amin NP
AU  - Ünsal-Kaçmaz K
AU  - Wang X
AU  - Li J
AU  - Loehr A
AU  - Pachynski RK
PY  - 2022
JO  - Journal for immunotherapy of cancer
DO  - 10.1136/jitc-2022-004761
UR  - https://doi.org/10.1136/jitc-2022-004761
ER  -

APA

K, F., M, R., DP, P., JC, G., J, P., L, L., S, Z., M, B., H, M., G, G., DA, B., SL, M., JC, V. L., EM, K., D, C., A, F., F, S., MO, G., DR, S., AJ, A., P, B., NP, A., K, Ü., X, W., J, L., A, L., & RK, P. (2022). Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial.. Journal for immunotherapy of cancer. https://doi.org/10.1136/jitc-2022-004761

Source records

pubmed · retrieved 2026-09-25T22:17:51.772Z